Role of Trimetazidine in Ameliorating Endothelial Dysfunction: A Review

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2024 Apr 27

PMID 38675424

Authors

Yusof Kamisah

Hamat H Che Hassan

Affiliations

Soon will be listed here.

Abstract

Endothelial dysfunction is a hallmark of cardiovascular diseases, contributing to impaired vasodilation, altered hemodynamics, and atherosclerosis progression. Trimetazidine, traditionally used for angina pectoris, exhibits diverse therapeutic effects on endothelial dysfunction. This review aims to elucidate the mechanisms underlying trimetazidine's actions and its potential as a therapeutic agent for endothelial dysfunction and associated cardiovascular disorders. Trimetazidine enhances vasodilation and hemodynamic function by modulating endothelial nitric oxide synthase activity, nitric oxide production, and endothelin-1. It also ameliorates metabolic parameters, including reducing blood glucose, mitigating oxidative stress, and dampening inflammation. Additionally, trimetazidine exerts antiatherosclerotic effects by inhibiting plaque formation and promoting its stability. Moreover, it regulates apoptosis and angiogenesis, fostering endothelial cell survival and neovascularization. Understanding trimetazidine's multifaceted mechanisms underscores its potential as a therapeutic agent for endothelial dysfunction and associated cardiovascular disorders, warranting further investigation for clinical translation.

Citing Articles

"Emerging clinical approaches in diabetic cardiomyopathy: insights from clinical trials and future directions".

Moka M, K S, George M Acta Diabetol. 2024; 62(1):1-10.

PMID: 39254745 DOI: 10.1007/s00592-024-02363-5.

References

Medina-Leyte D, Zepeda-Garcia O, Dominguez-Perez M, Gonzalez-Garrido A, Villarreal-Molina T, Jacobo-Albavera L . Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. Int J Mol Sci. 2021; 22(8). PMC: 8068178. DOI: 10.3390/ijms22083850. View

Yoon J, Cho B, Park H, Kang S, Choi S, Jang H . Differential effects of trimetazidine on vascular smooth muscle cell and endothelial cell in response to carotid artery balloon injury in diabetic rats. Int J Cardiol. 2012; 167(1):126-33. DOI: 10.1016/j.ijcard.2011.12.061. View

Belardinelli R, Lacalaprice F, Faccenda E, Volpe L . Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation. Eur J Cardiovasc Prev Rehabil. 2008; 15(5):533-40. DOI: 10.1097/HJR.0b013e328304feec. View

Syamsunarno M, Safitri R, Kamisah Y . Protective Effects of Linn. and Its Bioactive Compounds on Cardiovascular Organs. Front Pharmacol. 2021; 12:725745. PMC: 8479160. DOI: 10.3389/fphar.2021.725745. View

Bobescu E, Marceanu L, Dima L, Balan A, Strempel C, Covaciu A . Trimetazidine Therapy in Coronary Artery Disease: The Impact on Oxidative Stress, Inflammation, Endothelial Dysfunction, and Long-Term Prognosis. Am J Ther. 2021; 28(5):e540-e547. DOI: 10.1097/MJT.0000000000001430. View

Hohensinner P, Lenz M, Haider P, Mayer J, Richter M, Kaun C . Pharmacological inhibition of fatty acid oxidation reduces atherosclerosis progression by suppression of macrophage NLRP3 inflammasome activation. Biochem Pharmacol. 2021; 190:114634. DOI: 10.1016/j.bcp.2021.114634. View

Xu S, Ilyas I, Little P, Li H, Kamato D, Zheng X . Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacol Rev. 2021; 73(3):924-967. DOI: 10.1124/pharmrev.120.000096. View

Belardinelli R, Solenghi M, Volpe L, Purcaro A . Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect. Eur Heart J. 2007; 28(9):1102-8. DOI: 10.1093/eurheartj/ehm071. View

Cooper S, Teoh H, Campeau M, Verma S, Leask R . Empagliflozin restores the integrity of the endothelial glycocalyx in vitro. Mol Cell Biochem. 2019; 459(1-2):121-130. DOI: 10.1007/s11010-019-03555-2. View

10.

Chen W, Wu P, Yu F, Luo G, Qing L, Tang J . HIF-1α Regulates Bone Homeostasis and Angiogenesis, Participating in the Occurrence of Bone Metabolic Diseases. Cells. 2022; 11(22). PMC: 9688488. DOI: 10.3390/cells11223552. View

11.

Fragasso G, Piatti Md P, Monti L, Palloshi A, Setola E, Puccetti P . Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003; 146(5):E18. DOI: 10.1016/S0002-8703(03)00415-0. View

12.

Borowicz-Reutt K, Banach M . Trimetazidine, an Anti-Ischemic Drug, Reduces the Antielectroshock Effects of Certain First-Generation Antiepileptic Drugs. Int J Mol Sci. 2022; 23(19). PMC: 9570019. DOI: 10.3390/ijms231911328. View

13.

Kamisah Y, Fadhlullah Zuhair J, Juliana A, Jaarin K . Parkia speciosa empty pod prevents hypertension and cardiac damage in rats given N(G)-nitro-l-arginine methyl ester. Biomed Pharmacother. 2017; 96:291-298. DOI: 10.1016/j.biopha.2017.09.095. View

14.

Mustafa N, Jalil J, Zainalabidin S, Saleh M, Asmadi A, Kamisah Y . Molecular mechanisms of sacubitril/valsartan in cardiac remodeling. Front Pharmacol. 2022; 13:892460. PMC: 9393311. DOI: 10.3389/fphar.2022.892460. View

15.

Bai T, Li M, Liu Y, Qiao Z, Wang Z . Inhibition of ferroptosis alleviates atherosclerosis through attenuating lipid peroxidation and endothelial dysfunction in mouse aortic endothelial cell. Free Radic Biol Med. 2020; 160:92-102. DOI: 10.1016/j.freeradbiomed.2020.07.026. View

16.

Berkels R, Taubert D, Rosenkranz A, Rosen R . Vascular protective effects of dihydropyridine calcium antagonists. Involvement of endothelial nitric oxide. Pharmacology. 2003; 69(4):171-6. DOI: 10.1159/000073659. View

17.

Camare C, Pucelle M, Negre-Salvayre A, Salvayre R . Angiogenesis in the atherosclerotic plaque. Redox Biol. 2017; 12:18-34. PMC: 5312547. DOI: 10.1016/j.redox.2017.01.007. View

18.

Xie Y, Zhao H, Zhao M, Huang H, Liu C, Huang F . Effects of resistance exercise on blood glucose level and pregnancy outcome in patients with gestational diabetes mellitus: a randomized controlled trial. BMJ Open Diabetes Res Care. 2022; 10(2). PMC: 8984031. DOI: 10.1136/bmjdrc-2021-002622. View

19.

Yang Q, Li S, Zhou Z, Yang X, Liu Y, Hao K . Trimetazidine mitigates high glucose-induced retinal endothelial dysfunction by inhibiting PI3K/Akt/mTOR pathway-mediated autophagy. Bioengineered. 2022; 13(3):7515-7527. PMC: 8974130. DOI: 10.1080/21655979.2022.2048993. View

20.

Farzaei M, Ramezani-Aliakbari F, Ramezani-Aliakbari M, Zarei M, Komaki A, Shahidi S . Regulatory effects of trimetazidine in cardiac ischemia/reperfusion injury. Naunyn Schmiedebergs Arch Pharmacol. 2023; 396(8):1633-1646. DOI: 10.1007/s00210-023-02469-7. View